NCT00837369

Regadenoson R-T Perfusion Imaging Trial

Regadenoson Real Time Perfusion Imaging Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: University of Nebraska · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

To exam the feasibility and accuracy of Regadenoson real time perfusion (RTPE) Imaging during vasodilator stress with Regadenoson for detection of significant coronary artery disease (CAD) in patients scheduled to undergo coronary angiography.

Detailed description

To exam the feasibility and accuracy of RTPE during vasodilator stress with 400micrograms of the adenosine receptor (A2A) agonist Regadenoson for detection of significant coronary artery disease (CAD) in patients scheduled to undergo coronary angiography. Sensitivity, specificity , and accuracy of perfusion and wall motion analysis to identify a coronary stenosis\> 50% in diameter by quantitive angiography will be analyzed

Conditions

• Coronary Artery Disease
• Myocardial Perfusion Abnormalities

Interventions

Type	Name	Description
DRUG	Regadenoson	400ug IV bolus injection, single dosage

Timeline

• Start date: 2009-04-07
• Primary completion: 2011-03-01
• Completion: 2011-12-01
• First posted: 2009-02-05
• Last updated: 2024-12-27
• Results posted: 2024-12-24

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study